

N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma

Status Change – August 18, 2009

NOTICE OF STATUS CHANGE

This study is temporarily suspended to patient accrual effective Tuesday, August 18, 2009. Patient entry will not be permitted after August 18 at 3:30 CST until further notification is issued.

The study is closed per protocol design for evaluation of the next 3 patients enrolled at dose level -1 (extended cohort to 6 patients) and subsequent cycle 1 adverse events for the safety analysis phase of the trial.

The study will re-open to patient accrual at the completion of the evaluation and notification of the re-opening will be distributed at that time.

Please retain this notice with the protocol.